Alfa interferon is the first therapy for chronic hepatitis –C, and it was reported that autoimmune hepatitis could be triggered and exacerbated during interferon therapy. In this work, we found high prevalence of autoimmune markers (47.2%) in chronic hepatitis –C patients, but they had no significant effect on the biochemical and virologic responses to interferon therapy. Also they had no significant effect on the histopathological changes in liver biopsy studies. So, the presence of the autoimmune markers should not affect the decision to treat those patients with interferon, but close follow up is necessary whenever interferon therapy is initiated.